Afficher la notice abrégée

dc.contributor.authorLE BARZ, Melanie
dc.contributor.authorANHE, Fernando F.
dc.contributor.authorVARIN, Thibaut V.
dc.contributor.authorDESJARDINS, Yves
dc.contributor.authorLEVY, Emile
dc.contributor.authorROY, Denis
hal.structure.identifierChimie et Biologie des Membranes et des Nanoobjets [CBMN]
dc.contributor.authorURDACI, Maria C.
ORCID: 0000-0002-0868-0050
IDREF: 033307679
dc.contributor.authorMARETTE, Andre
dc.date.accessioned2020-09-03T08:02:06Z
dc.date.available2020-09-03T08:02:06Z
dc.date.issued2015
dc.identifier.issn2233-6079
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/10966
dc.description.abstractEnOver the past decade, growing evidence has established the gut microbiota as one of the most important determinants of metabolic disorders such as obesity and type 2 diabetes. Indeed, obesogenic diet can drastically alter bacterial populations (i.e., dysbiosis) leading to activation of pro-inflammatory mechanisms and metabolic endotoxemia, therefore promoting insulin resistance and cardiometabolic disorders. To counteract these deleterious effects, probiotic strains have been developed with the aim of reshaping the microbiome to improve gut health. In this review, we focus on benefits of widely used probiotics describing their potential mechanisms of action, especially their ability to decrease metabolic endotoxemia by restoring the disrupted intestinal mucosal barrier. We also discuss the perspective of using new bacterial strains such as butyrate-producing bacteria and the mucolytic Akkermansia muciniphila, as well as the use of prebiotics to enhance the functionality of probiotics. Finally, this review introduces the notion of genetically engineered bacterial strains specifically developed to deliver anti-inflammatory molecules to the gut.
dc.language.isoen
dc.title.enProbiotics as Complementary Treatment for Metabolic Disorders
dc.typeArticle de revue
dc.identifier.doi10.4093/dmj.2015.39.4.291
dc.subject.halChimie/Matériaux
bordeaux.journalDiabetes & metabolism journal
bordeaux.page291-303
bordeaux.volume39
bordeaux.hal.laboratoriesInstitut de Chimie & de Biologie des Membranes & des Nano-objets (CBMN) - UMR 5248*
bordeaux.hal.laboratoriesInstitut de Chimie & de Biologie des Membranes & des Nano-objets (CBMN, UMR 5248)
bordeaux.issue4
bordeaux.institutionUniversité de Bordeaux
bordeaux.institutionBordeaux INP
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Diabetes%20&%20metabolism%20journal&rft.date=2015&rft.volume=39&rft.issue=4&rft.spage=291-303&rft.epage=291-303&rft.eissn=2233-6079&rft.issn=2233-6079&rft.au=LE%20BARZ,%20Melanie&ANHE,%20Fernando%20F.&VARIN,%20Thibaut%20V.&DESJARDINS,%20Yves&LEVY,%20Emile&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée